BriaCell Therapeutics Stock (NASDAQ:BCTX)

Revenue Financials Chart

Previous Close

$4.09

52W Range

$4.01 - $98.20

50D Avg

$6.99

200D Avg

$14.46

Market Cap

$7.67M

Avg Vol (3M)

$417.15K

Beta

2.03

Div Yield

BCTX Company Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 14, 2012

Website

BCTX Performance

BCTX Financial Summary

	Jul 25	Jul 24	Jul 23
Revenue	-	-	-
Operating Income	-	$-46.02K	$-23.27M
Net Income	$-26.31M	$-6.62K	$-20.30M
EBITDA	-	$-45.91K	$-22.37M
Basic EPS	-	$-4.28	$-19.79
Diluted EPS	-	$-4.28	$-19.79

Fiscal year ends in Jul 25 | Currency in USD

Peer Comparison

Ticker	Company
ASBP	Aspire Biopharma Holdings, Inc.
HOTH	Hoth Therapeutics, Inc.
MBRX	Moleculin Biotech, Inc.
PCSA	Processa Pharmaceuticals, Inc.
CRIS	Curis, Inc.
LPTX	Leap Therapeutics, Inc.
ALLR	Allarity Therapeutics, Inc.
CTXR	Citius Pharmaceuticals, Inc.
PALI	Palisade Bio, Inc.